FDA requests more Phase II rAAT analyses

PPL (LSE:PTH) said that in a meeting with partner Bayer (FSE:BAYG), FDA requested further analyses of a Phase II study of PTH's recombinant alpha 1-antitrypsin (rAAT) replacement therapy given using B...